Patent 12133844 was granted and assigned to Abraxis BioScience on November, 2024 by the United States Patent and Trademark Office.
The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.